

Protocadherin-7 contributes to maintenance of bone homeostasis through regulation of osteoclast multinucleation

Hyunsoo Kim^{1,#}, Noriko Takegahara^{1,#}, Matthew C. Walsh¹, Jun Ueda², Yoshitaka Fujihara², Masahito Ikawa² & Yongwon Choi^{1,*}

¹Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA, ²Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan

Osteoclasts are hematopoietic-derived cells that resorb bone. They are required to maintain proper bone homeostasis and skeletal strength. Although osteoclast differentiation depends on receptor activator of NF- κ B ligand (RANKL) stimulation, additional molecules further contribute to osteoclast maturation. Here, we demonstrate that protocadherin-7 (Pcdh7) regulates formation of multinucleated osteoclasts and contributes to maintenance of bone homeostasis. We found that Pcdh7 expression is induced by RANKL stimulation, and that RNAi-mediated knockdown of Pcdh7 resulted in impaired formation of osteoclasts. We generated Pcdh7-deficient mice and found increased bone mass due to decreased bone resorption but without any defect in bone formation. Using an *in vitro* culture system, it was revealed that formation of multinucleated osteoclasts is impaired in Pcdh7-deficient cultures, while no apparent defects were observed in differentiation and function of Pcdh7-deficient osteoblasts. Taken together, these results reveal an osteoclast cell-intrinsic role for Pcdh7 in maintaining bone homeostasis. [BMB Reports 2020; 53(9): 472-477]

INTRODUCTION

Skeletal homeostasis is maintained via continuous bone formation mediated by osteoblasts and bone destruction mediated by osteoclasts (1). Under pathogenic conditions, excessive osteoclast activity is often observed, which can cause pathogenic bone loss such as is observed in osteoporosis, periodontitis, and rheumatoid arthritis (2-4). Therefore, understanding the cellular and molecular mechanisms that regulate osteoclast

differentiation and function will contribute to our knowledge of osteoclast biology, and further provide molecular bases for designing therapeutic strategies for bone diseases that are accompanied by bone destruction.

Osteoclasts are specialized multinucleated giant cells that originate from myeloid progenitors (5). Differentiation of osteoclasts is initiated primarily by the osteoclast differentiation factor RANKL (6), but the process further requires cell surface molecules to mediate cell adhesion and promote osteoclast multinucleation (7), which is itself a hallmark of osteoclast maturation (8). One of the principal factors at sites of cell-cell contact are cadherins. Cadherins are transmembrane, calcium-dependent adhesion molecules that regulate cell-cell contact through homophilic or heterophilic interactions between compatible cadherin extracellular regions (9, 10). The cadherin superfamily consists of classical cadherins, desmosomal cadherins, and protocadherins.

Previously, we reported comparative gene expression profiling designed to identify potential genes that regulate osteoclast maturation through use of multinucleation as a functional readout (8). As a result, the gene *Pcdh7*, which encodes the protein protocadherin 7 (Pcdh7) was identified (Supplementary Fig. 1). Pcdh7 is a member of non-clustered protocadherin δ 1 subgroup of the cadherin superfamily (11, 12). It has seven cadherin-like ectodomains, a single transmembrane domain and a C-terminal intracellular domain (13). The expression of *Pcdh7* has been identified in osteoclasts, and a potential regulatory role in osteoclast multinucleation has been revealed by RNAi-mediated gene knockdown (14). However, the function of Pcdh7 in regulation of osteoclast differentiation *in vivo* and its role in bone homeostasis still remain unclear.

Here, we demonstrate that Pcdh7, expression of which is induced by RANKL stimulation, functions as a regulator of bone homeostasis through regulation of osteoclast multinucleation. Gene deletion of *Pcdh7* resulted in increased bone mass with reduction of osteoclasts but not of osteoblasts in mice. No apparent defects in bone formation were observed. Using *in vitro* cell culture systems, we showed that *Pcdh7* deficiency results in impaired formation of multinucleated osteoclasts, and that the defect could be restored by retroviral transduction of *Pcdh7*. By contrast, *Pcdh7* deficiency did not show signifi-

*Corresponding author. Tel: +1-215-746-6404; Fax: +1-215-573-0888; E-mail: ychoi3@pennmedicine.upenn.edu

[#]These authors contributed equally to this work.

<https://doi.org/10.5483/BMBRep.2020.53.9.050>

Received 6 March 2020, Revised 26 March 2020,
Accepted 6 April 2020

Keywords: Bone homeostasis, Maturation, Multinucleation, Osteoclast, Pcdh7

cant differences in differentiation or function of osteoblasts. Collectively, these results demonstrate that *Pcdh7* controls osteoclast multinucleation/maturation and contributes to maintenance of bone homeostasis.

RESULTS

Pcdh7 is involved in *in vitro* osteoclast differentiation

In order to understand the role of *Pcdh7* in osteoclasts, expression dynamics of *Pcdh7* during osteoclast differentiation were examined. Mouse bone marrow-derived monocytes (BMMs) were treated with M-CSF + RANKL for up to three days to induce osteoclasts, and then western blotting was performed. Expression of PCDH7 protein was induced, and peaked on day one of culture (Fig. 1A). Next, we investigated the role of *Pcdh7* in osteoclasts by RNAi experiments using retrovirus encoding shRNA for *Pcdh7*. BMMs retrovirally transduced with shRNA for *Pcdh7* showed significant reductions in tartrate-resistant acidic phosphatase positive (TRAP⁺) multinucleated cells (i.e., mature osteoclasts) (Fig. 1B), consistent with a previous report (14). These results suggested a potential regulatory function of *Pcdh7* in osteoclast maturation.

Pcdh7 regulates bone homeostasis

To better understand the role of *Pcdh7* in osteoclasts and its function in bone remodeling, *Pcdh7*-deficient (*Pcdh7*^{-/-}) mice were generated using clustered regularly interspersed short palindromic repeats (CRISPR)/Cas9 technology (Supplementary Fig. 2A). Gene knockout mice carrying deletions of 14 base

pairs (bps) in exon 1 of *Pcdh7* were obtained (Supplementary Fig. 2B). We verified mouse genotypes by genome sequencing, and also confirmed successful gene deletion of *Pcdh7* in




Fig. 1. Identification of *Pcdh7* as an osteoclast differentiation associated gene. (A) PCDH7 protein expression during osteoclast differentiation. Total cell lysates were prepared from BMMs cultured with M-CSF + RANKL for the indicated days and used for western blotting with the indicated antibodies. (B) Effect of *Pcdh7* RNAi on osteoclast differentiation. BMMs retrovirally transduced with the indicated shRNAs were cultured with M-CSF + RANKL for three days. Relative expression of *Pcdh7* was determined by Q-PCR (left). Cells were stained for TRAP (middle). Frequency of TRAP⁺ multinucleated cells is shown (right). Scale bar represents 100 μ m.




Fig. 2. *Pcdh7* deficiency results in increased bone mass in mice. (A) Microcomputed tomography (μ CT) images of femurs from *Pcdh7*^{+/+} and *Pcdh7*^{-/-} mice. The femurs of 12-week-old male mice were analyzed. Bone volume per tissue volume (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular spacing (Tb.Sp) are shown. (B) Microcomputed tomography (μ CT) images of femur cortical thickness (Ct.Th) from 12-week-old male *Pcdh7*^{+/+} and *Pcdh7*^{-/-} mice is shown. (C) Dynamic histomorphometry of tibias from 12-week-old *Pcdh7*^{+/+} and *Pcdh7*^{-/-} mice. Mineral apposition rate (MAR) and bone formation (BFR) are shown. Scale bar represents 50 μ m. (D) Histological analysis of tibias from 12-week-old *Pcdh7*^{+/+} and *Pcdh7*^{-/-} mice. Tibial sections were stained with TRAP or H&E. Osteoclast number per bone surface (N.Oc/BS) and osteoblast number per bone surface (N.Ob/BS) are shown. Data are shown as mean \pm S.D. *P < 0.05, **P < 0.01, ***P < 0.001.

Pcdh7^{-/-} cultures by western blotting (Supplementary Fig. 2C).

In order to examine the impact of *Pcdh7* deficiency on bone homeostasis, gender- and age-matched *Pcdh7*^{+/+} and *Pcdh7*^{-/-} mice were prepared and representative 3D trabecular bone reconstruction analyses were performed. Bone microstructure imaging by high-resolution microcomputed tomography (μ CT) of *Pcdh7*^{-/-} mice revealed increases in bone mass, characterized by augmented bone indices including trabecular bone volume per tissue volume (BV/TV) and trabecular thickness (Tb.Th), with concomitant decreases in trabecular spacing (Tb.Sp) (Fig. 2A). Trabecular number (Tb.N) was comparable between *Pcdh7*^{+/+} and *Pcdh7*^{-/-} mice (Fig. 2A). There were no signifi-

cant differences in cortical bone thickness (Ct.Th) between *Pcdh7*^{+/+} and *Pcdh7*^{-/-} mice (Fig. 2B). Dynamic histomorphometry by sequential injection of calcein and xylenol orange revealed that bone formation rates is normal in *Pcdh7*^{-/-} mice (Fig. 2C). Osteoclasts and osteoblasts in *Pcdh7*^{+/+} and *Pcdh7*^{-/-} mice were enumerated using bone sections. TRAP-stained bone sections exhibited a reduction in osteoclast numbers on the bone surface (N.Oc/BS) in *Pcdh7*^{-/-} bone compared to numbers in *Pcdh7*^{+/+} (Fig. 2D). By contrast, quantitation of osteoblast numbers per bone surface (N.Ob/BS) revealed comparable numbers of osteoblasts in bone sections between *Pcdh7*^{+/+} and *Pcdh7*^{-/-} mice (Fig. 2D). These results suggest




Fig. 3. *Pcdh7* deficiency results in impaired osteoclast differentiation but not osteoblast differentiation or function. (A) Relative expression of *Pcdh7* in BMMs, osteoclasts (three days culture with M-CSF + RANKL), BMSCs, and osteoblasts (14 days culture with glycerophosphate + ascorbic acid). Total RNAs were collected and expression of *Pcdh7* was measured by Q-PCR. (B) Osteoclast differentiation of *Pcdh7*^{+/+} and *Pcdh7*^{-/-} cells. BMMs were cultured with M-CSF + RANKL for three days. Frequency of TRAP⁺ multinucleated cells (3 nuclei or more per cell) and hyper-multinucleated cells (>100 μ m) are shown. (C) Gene expression during osteoclast differentiation. Total RNAs were collected from *Pcdh7*^{+/+} and *Pcdh7*^{-/-} cultures and indicated genes were measured by Q-PCR. (D) Bone resorption activity of *Pcdh7*^{+/+} and *Pcdh7*^{-/-} osteoclasts. Resorption area per cell is shown. (E) Osteoclast differentiation rescued by retroviral transduction of *Pcdh7* in *Pcdh7*^{-/-} BMMs. BMMs were retrovirally transduced with empty vector (EV) or Flag-tagged *Pcdh7* expression vector followed by culture with M-CSF + RANKL for three days. Frequency of TRAP⁺ multinucleated cells (3 nuclei or more per cell) is shown. Expression of exogenous *Pcdh7* was confirmed by western blotting with anti-Flag antibody. (F) *Pcdh7*^{+/+} and *Pcdh7*^{-/-} BMSCs were cultured with osteogenic medium for the indicated days, and then stained with alizarin red. (G) Gene expression during osteoblast differentiation. Total RNAs were collected from *Pcdh7*^{+/+} and *Pcdh7*^{-/-} cultures and indicated genes were measured by Q-PCR. (H) *Pcdh7*^{+/+} and *Pcdh7*^{-/-} BMMs and BMSC-derived osteoblasts were cocultured in the presence of 1,25-dihydroxyvitamin D3 and prostaglandin E2, and the formation of multinucleated osteoclasts was determined by TRAP staining. Frequency of TRAP⁺ multinucleated cells (3 nuclei or more per cell) are shown. Data are shown as mean \pm S.D. *P < 0.05, ****P < 0.001.

that *Pcdh7* deficiency results in increased bone mass with impaired osteoclast differentiation but apparently normal osteoblast development and function in male mice.

Cell-intrinsic role of *Pcdh7* in osteoclast differentiation

To further characterize the specific cell-intrinsic role of *Pcdh7*, osteoclasts and osteoblasts were generated *in vitro*, and differentiation and cellular functions were examined. First, expression levels of *Pcdh7* message in osteoclasts and osteoblasts were examined. *Pcdh7*^{+/+} BMMs or bone marrow-derived stromal cells (BMSCs) were cultured, respectively, with M-CSF + RANKL to generate osteoclasts, or with glycerophosphate + ascorbic acid to generate osteoblasts. *Pcdh7* message was significantly increased in osteoclasts cultures compared to levels in BMMs, while *Pcdh7* message levels were lower in BMSCs or BMSC-derived osteoblasts than in BMMs (Fig. 3A). Next, osteoclasts were generated from *Pcdh7*^{+/+} and *Pcdh7*^{-/-} BMMs with M-CSF + RANKL. Significant reductions in the frequency of multinucleated (>3 nuclei per cell) TRAP⁺ cells in *Pcdh7*^{-/-} cultures were observed compared to *Pcdh7*^{+/+} cultures (Fig. 3B). Message levels of osteoclast differentiation markers, *Acp5* and *Ctsk*, were comparable between *Pcdh7*^{+/+} and *Pcdh7*^{-/-} cultures (Fig. 3C). Formation of pit area per mature osteoclasts was slightly reduced in *Pcdh7*^{-/-} cultures (Fig. 3D). These results suggest that *Pcdh7* is required for osteoclast multinucleation rather than for differentiation or bone resorbing functions. Retroviral transduction of *Pcdh7*^{-/-} BMMs with full-length *Pcdh7* completely rescued TRAP⁺ multinucleated cell formation in *Pcdh7*^{-/-} cultures (Fig. 3E), suggesting that the phenotypes observed in *Pcdh7*^{-/-} osteoclast cultures can be solely attributed to deletion of the *Pcdh7* gene.

Next, osteoblasts were generated from *Pcdh7*^{+/+} and *Pcdh7*^{-/-} BMSCs with glycerophosphate + ascorbic acid. *In vitro* osteogenic differentiation assays with alizarin red staining revealed no differences in terms of mineralized nodule formation and calcium deposits in *Pcdh7*^{+/+} and *Pcdh7*^{-/-} osteoblasts (Fig. 3F). Message levels of osteoblast differentiation markers such as *Alpl*, osteocalcin (also known as *Bglap*), and *Bmp2* were also comparable between *Pcdh7*^{+/+} and *Pcdh7*^{-/-} cells (Fig. 3G). Additionally, when BMSC-derived osteoblasts were co-cultured with BMMs in the presence of 1,25-dihydroxyvitamin D3 + prostaglandin E2, *Pcdh7*^{-/-} osteoblasts promoted the formation of *Pcdh7*^{+/+} osteoclasts to the same extent as *Pcdh7*^{+/+} osteoblasts (Fig. 3H). These results suggest that *Pcdh7* is not required for osteoblast differentiation or function. Taken together, these results clarify the role of *Pcdh7* in bone homeostasis as a regulator of osteoclast multinucleation/maturation, but not of osteoblast differentiation or function.

DISCUSSION

Cell-cell interaction through surface receptors is required for proper osteoclast differentiation and multinucleation (7, 15-17). In this study, we demonstrated that *Pcdh7*, a transmembrane

protein belonging to the protocadherins within the cadherin superfamily, is required for proper bone homeostasis through regulation of osteoclast multinucleation/maturation (Fig. 4). We generated *Pcdh7* gene deletion mice and revealed that *Pcdh7* deficiency resulted in increased bone mass without affecting bone formation in male mice. Determining whether the requirement for *Pcdh7* for proper bone homeostasis is influenced by sexual difference will need further investigation. Employing an *in vitro* culture system using *Pcdh7*-deficient cells further revealed a requirement for *Pcdh7* in osteoclast multinucleation, while *Pcdh7* deficiency resulted in no significant impact on osteoblast differentiation or function. A previous report identified *Pcdh7* as a gene that is epigenetically regulated during osteoclastogenesis, and implied a role for *Pcdh7* in osteoclast multinucleation (14). Our findings reported here are consistent with those previously reported findings with respect to the role of *Pcdh7* in osteoclast multinucleation, and provide the first *in vivo* evidence of involvement of *Pcdh7* in bone homeostasis.

We have identified an osteoclast cell-intrinsic role of *Pcdh7*. However, the principal function and molecular mechanism of *Pcdh7* in the context of osteoclast differentiation/multinucleation still remain to be determined. Cadherins function by mediating cell-cell adhesion through homophilic interactions, whereas protocadherins appear to have more varied physiological functions as mediators of both cell-cell adhesion and as regulators of signaling molecules (12, 18, 19). Indeed, in addition to exhibiting binding capacity via homophilic interactions (20), *Pcdh7* has been shown to control signal transduction pathways via binding cytoplasmic signaling molecules such as SET (also known as TAF1) and PP2a (21). Involvement of PP2a in osteoclasts has been shown using a chemical inhibitor (22), and the findings suggest that *Pcdh7* regulates PP2a during osteoclast differentiation. There is another possibility that the *Pcdh7* intracellular region recruits additional signaling




Fig. 4. A summarizing diagram. Deficiency of *Pcdh7* results in increased bone mass with reduction of osteoclasts but not of osteoblasts in mice.

molecules. Pcdh7 has been shown to express four unique isoforms with different cytoplasmic tails that are generated by alternative splicing (23). It is unclear which isoform(s) is expressed in osteoclasts, and whether the different isoforms have functional differences. Further studies will be required to understand the molecular mechanisms of Pcdh7-mediated regulation of osteoclast maturation.

Bone remodeling is tightly controlled by coupling between bone resorbing osteoclasts and bone forming osteoblasts (24, 25). Coupling is critical for preserving bone architecture and strength. Current treatments for bone loss such as bisphosphonate and anti-RANKL antibody (Denosmab), which primarily target early osteoclast commitment and/or viability (26), often fail to uncouple bone degradation and formation. Consequently, bone strength is compromised due to unintended inhibition of coupled bone formation (27). In this study, we report having identified Pcdh7 in the process of searching for genes related to the maturation/late stage of osteoclast development, which we believe will lead to better treatment targets (i.e., inhibition of osteoclastic bone resorption without preventing osteoblastic new bone formation), and we have shown that Pcdh7 uncouples bone degradation and formation. Our results suggest that Pcdh7 might be a good candidate target for selectively inhibiting bone loss.

Taken together, although a full understanding of how Pcdh7 contributes to osteoclast differentiation remains to be addressed, we provide evidence of a non-redundant function for Pcdh7 in osteoclast multinucleation/maturation and bone homeostasis. Pcdh7 may be a promising candidate for a therapeutic target for bone diseases.

MATERIALS AND METHODS

Detailed information is provided in the Supplementary Information.

ACKNOWLEDGEMENTS

This work was supported in part by the Penn Center for Musculoskeletal Disorders Histology Core (NIH P30-AR069619).

CONFLICTS OF INTEREST

The authors have no conflicting interests.

REFERENCES

1. Teitelbaum SL and Ross FP (2003) Genetic regulation of osteoclast development and function. *Nat Rev Genet* 4, 638-649
2. Moutsopoulos NM, Konkel J, Sarmadi M et al (2014) Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. *Sci Transl Med* 6, 229ra40
3. Souza PP and Lerner UH (2013) The role of cytokines in inflammatory bone loss. *Immunol Invest* 42, 555-622
4. Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. *Nat Rev Immunol* 7, 292-304
5. Walsh MC, Kim N, Kadono Y et al (2006) Osteoimmunology: interplay between the immune system and bone metabolism. *Annu Rev Immunol* 24, 33-63
6. Boyle JW, Simonet SW and Lacey LD (2003) Osteoclast differentiation and activation. *Nature* 423, 337-342
7. Aguilar PS, Baylies MK, Fleissner A et al (2013) Genetic basis of cell-cell fusion mechanisms. *Trends Genet* 29, 427-437
8. Kim H, Walsh MC, Takegahara N et al (2017) The purinergic receptor P2X5 regulates inflammasome activity and hyper-multinucleation of murine osteoclasts. *Sci Rep* 7, 196
9. Takeichi M (2014) Dynamic contacts: rearranging adherens junctions to drive epithelial remodelling. *Nat Rev Mol Cell Biol* 15, 397-410
10. Leckband DE and de Rooij J (2014) Cadherin adhesion and mechanotransduction. *Annu Rev Cell Dev Biol* 30, 291-315
11. Hayashi S and Takeichi M (2015) Emerging roles of protocadherins: from self-avoidance to enhancement of motility. *J Cell Sci* 128, 1455-1464
12. Kim SY, Yasuda S, Tanaka H, Yamagata K and Kim H (2011) Non-clustered protocadherin. *Cell Adh Migr* 5, 97-105
13. Peek SL, Mah KM and Weiner JA (2017) Regulation of neural circuit formation by protocadherins. *Cell Mol Life Sci* 74, 4133-4157
14. Nakamura H, Nakashima T, Hayashi M et al (2014) Global epigenomic analysis indicates protocadherin-7 activates osteoclastogenesis by promoting cell-cell fusion. *Biochem Biophys Res Commun* 455, 305-311
15. Helming L and Gordon S (2009) Molecular mediators of macrophage fusion. *Trends Cell Biol* 19, 514-522
16. Oren-Suissa M and Podbilewicz B (2007) Cell fusion during development. *Trends Cell Biol* 17, 537-546
17. Kim H, Takegahara N, Walsh MC et al (2020) IgSF11 regulates osteoclast differentiation through association with the scaffold protein PSD-95. *Bone Res* 8, 5
18. Kahr I, Vandepoele K and van Roy F (2013) Delta-protocadherins in health and disease. *Prog Mol Biol Transl Sci* 116, 169-192
19. Heggem M and Bradley R (2003) The cytoplasmic domain of Xenopus NF-protocadherin interacts with TAF1/set. *Dev Cell* 4, 419-429
20. Bradley R, Espeseth A and Kintner C (1998) NF-protocadherin, a novel member of the cadherin superfamily, is required for Xenopus ectodermal differentiation. *Curr Biol* 8, 325-334
21. Zhou X, Updegraff BL, Guo Y et al (2017) PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis. *Cancer Res* 77, 187-197
22. Wang L, Guo X, Zhou W et al (2018) Protein phosphatase 2A as a new target for downregulating osteoclastogenesis and alleviating titanium particle-induced bone resorption. *Acta Biomater* 73, 488-499
23. Vanhalst K, Kools P, Staes K, van Roy F and Redies C (2005) delta-Protocadherins: a gene family expressed differentially in the mouse brain. *Cell Mol Life Sci* 62,

- 1247-1259
24. Zaidi M (2007) Skeletal remodeling in health and disease. *Nat Med* 13, 791-801
 25. Matsuo K and Irie N (2008) Osteoclast-osteoblast communication. *Arch Biochem Biophys* 473, 201-209
 26. Miyazaki T, Tokimura F and Tanaka S (2014) A review of denosumab for the treatment of osteoporosis. *Patient Prefer Adherence* 8, 463-471
 27. Baron R, Ferrari S and Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. *Bone* 48, 677-692